CoChat

Design of Phase I Combination Trials: Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee

Open access
Paller, Channing J., Bradbury, Penelope A., Ivy, S. Percy, Seymour, Lesley, LoRusso, Patricia M., Baker, Laurence, Rubinstein, Larry, Huang, Erich, Collyar, Deborah, Groshen, Susan, Reeves, Steven, Ellis, Lee M., Sargent, Daniel J., Rosner, Gary L., LeBlanc, Michael L., Ratain, Mark J. · 2014 · Clinical Cancer Research
Cited by 84

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

Anticancer drugs are combined in an effort to treat a heterogeneous tumor or to maximize the pharmacodynamic effect. The development of combination regimens, while desirable, poses unique challenges. These include the selection of agents for combination therapy that may lead to improved efficacy while maintaining acceptable toxicity, the design of clinical trials that provide informative results for individual agents and combinations, and logistic and regulatory challenges. The phase I trial is often the initial step in the clinical evaluation of a combination regimen. In view of the importance of combination regimens and the challenges associated with developing them, the Clinical Trial Design (CTD) Task Force of the National Cancer Institute Investigational Drug Steering Committee developed a set of recommendations for the phase I development of a combination regimen. The first two recommendations focus on the scientific rationale and development plans for the combination regimen; subsequent recommendations encompass clinical design aspects. The CTD Task Force recommends that selection of the proposed regimens be based on a biologic or pharmacologic rationale supported by clinical and/or robust and validated preclinical evidence, and accompanied by a plan for subsequent development of the combination. The design of the phase I clinical trial should take into consideration the potential pharmacokinetic and pharmacodynamic interactions as well as overlapping toxicity. Depending on the specific hypothesized interaction, the primary endpoint may be dose optimization, pharmacokinetics, and/or pharmacodynamics (i.e., biomarker). Clin Cancer Res; 20(16); 4210–7. ©2014 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-14-0521

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 84

Metadata

Authors
Paller, C. J., Bradbury, P. A., Ivy, S. P., Seymour, L., LoRusso, P. M., Baker, L., Rubinstein, L., Huang, E., Collyar, D., Groshen, S., Reeves, S., Ellis, L. M., Sargent, D. J., Rosner, G. L., LeBlanc, M. L., & Ratain, M. J.
Venue
Clinical Cancer Research
Published
2014-08-13
Volume
20
Issue
16
Pages
4210-4217
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2013520562
Cited by
84
References
14
FWCI
6.87
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Design of Phase I Combination Trials: Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-14-0521
The paper
Paller, C. J., Bradbury, P. A., Ivy, S. P., Seymour, L., LoRusso, P. M., Baker, L., Rubinstein, L., Huang, E., Collyar, D., Groshen, S., Reeves, S., Ellis, L. M., Sargent, D. J., Rosner, G. L., LeBlanc, M. L., & Ratain, M. J. (2014). Design of Phase I Combination Trials: Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-14-0521

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.